Patents by Inventor Weijuan Kan

Weijuan Kan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11873292
    Abstract: The present invention relates to the fields of medicinal chemistry and pharmacotherapy, and specifically relates to the chemical compound of formula (I), and its racemate, R-isomer, S-isomer, pharmaceutically acceptable salt, and mixtures thereof, as well as its method for preparation, a pharmaceutical composition containing said chemical compound, and use as a lysine-specific demethylase 1 (LSD 1) inhibitor. The cyclopropylamine chemical compound to which the present invention relates may be used in the treatment of cancer.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: January 16, 2024
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Hong Liu, Jia Li, Wei Zhu, Yubo Zhou, Jiang Wang, Mingbo Su, Shuni Wang, Wei Xu, Chunpu Li, Weijuan Kan, Hualiang Jiang, Kaixian Chen
  • Publication number: 20220041576
    Abstract: The present invention relates to a polysubstituted isoindoline compound as shown in general formula (I), and a preparation method, a pharmaceutical composition and the use thereof. In particular, the polysubstituted isoindoline compound is provided in the present invention as a class of novel CRL4CRBN E3 ubiquitin ligase modulators in structure, wherein same has a stronger antitumor activity and antitumor spectrum, and can be used to prepare drugs for treating CRL4CRBN E3 ligase-related diseases.
    Type: Application
    Filed: September 30, 2019
    Publication date: February 10, 2022
    Inventors: Xiaohua CHEN, Jia LI, Yu CHENG, Yubo ZHOU, Huijun NIE, Yujie WANG, Hongtao TIAN, Weijuan KAN, Tian MI, Xiaobei HU, Binshan ZHOU, Kenian YAN, Gaoya XU, Yuhua ZHONG, Lei FENG
  • Publication number: 20220041578
    Abstract: The present invention relates to an isoindoline compound as represented by general formula (I) and used as a CRBN regulator, and a preparation method, a pharmaceutical composition, and an application of the isoindoline compound. Specifically, a class of polysubstituted isoindoline compound provided in the present invention, as a class of CRL4CRBN E3 ubiquitin ligase regulator having a novel structure, has good anti-tumor activity and immunoregulatory activity, and can be used for preparing drugs for treating diseases associated with a CRL4CRBN E3 ubiquitin ligase.
    Type: Application
    Filed: December 6, 2019
    Publication date: February 10, 2022
    Inventors: Xiaohua CHEN, Jia LI, Yu CHENG, Yubo ZHOU, Huijun NIE, Yujie WANG, Andi GUO, Weijuan KAN
  • Publication number: 20220017505
    Abstract: Provided by the present disclosure are an amino quinazolinone and amino isoquinolone derivatives. It is verified by numerous experiments that the compounds provided by the present disclosure have good inhibiting effects on PI3K? and PI3K?, most of the compounds have prominent inhibiting effect on PI3K?, and show strong growth inhibiting effect on PIK3CA mutant tumor cells such as human breast cancer cell strain (MCF7). Therefore, the amino quinazolinone and amino isoquinolone derivatives according to the present disclosure can be applied in the preparation of anti-tumor and anti-inflammatory medicines, and can be used as PI3K? inhibitors in the preparation of medicines for treatment of human or animal cell proliferation related tumors, the medicines comprising the derivatives any one or more of pharmaceutically acceptable salts and solvates thereof as well as pharmaceutically acceptable carriers.
    Type: Application
    Filed: June 25, 2021
    Publication date: January 20, 2022
    Inventors: Rong SHENG, Jia LI, Dongyan GU, Yubo ZHOU, Jun WEI, Mengmeng ZHANG, Yongzhou HU, Kaixiang ZHANG, Jieyu LIU, Weijuan KAN
  • Publication number: 20190210998
    Abstract: The present invention relates to the fields of medicinal chemistry and pharmacotherapy, and specifically relates to the chemical compound of formula (I), and its racemate, R-isomer, S-isomer, pharmaceutically acceptable salt, and mixtures thereof, as well as its method for preparation, a pharmaceutical composition containing said chemical compound, and use as a lysine-specific demethylase 1 (LSD 1) inhibitor. The cyclopropylamine chemical compound to which the present invention relates may be used in the treatment of cancer.
    Type: Application
    Filed: June 2, 2017
    Publication date: July 11, 2019
    Applicant: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Hong Liu, Jia Li, Wei Zhu, Yubo Zhou, Jiang Wang, Mingbo Su, Shuni Wang, Wei Xu, Chunpu Li, Weijuan Kan, Hualiang Jiang, Kaixian Chen